The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Signal transducer and activator of transcription 3 (STAT3) is one of the crucial transcription factors, responsible for regulating cellular proliferation, cellular differentiation, migration, programmed cell death, inflammatory response, angiogenesis, and immune activation. In this review, we have discussed the classical regulation of STAT3 via diverse growth factors, cytokines, G‐protein‐coupled receptors, as well as toll‐like receptors. We have also highlighted the potential role of noncoding RNAs in regulating STAT3 signaling. However, the deregulation of STAT3 signaling has been found to be associated with the initiation and progression of both solid and hematological malignancies. Additionally, hyperactivation of STAT3 signaling can maintain the cancer stem cell phenotype by modulating the tumor microenvironment, cellular metabolism, and immune responses to favor drug resistance and metastasis. Finally, we have also discussed several plausible ways to target oncogenic STAT3 signaling using various small molecules derived from natural products.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Darnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080 · cited 1×
“The Janus kinase–signal transducer and activator of transcription (JAK–STAT) signaling pathway was originally reported as a downstream phosphorylation cascade initiated by interferon‐α (IFNα) and interleukin‐6 (IL‐6).(1,2) To date, seven members of the STAT protein family: STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, S…”
BackgroundThe emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926
Natural products as sources of new drugs over the last 25 years
Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467 · cited 1×
“It is mediated by several growth factors including VEGF, PDGF, and angiopoietins.(112,113) Among these growth factors, VEGF has been reported to be one of the most crucial mediators of tumor neovascularization.”
BackgroundA cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994) · Nature · doi:10.1038/367645a0 · Cited by 4,783
Natural products as sources of new drugs over the 30 years from 1981 to 2010
Newman, D. J., & Cragg, G. M. (2012) · Journal of Natural Products · doi:10.1021/np200906s · Cited by 4,687
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383 · cited 5×
“During the last decade, the implication of STAT3 in TME has been displayed to crucial in a variety of tumors due to its involvement in immune regulation.148 Overexpression of STAT3 was observed in tumor and tumor‐promoting immune cells.149 IL‐6/STAT3 pathway has been reported to provide an immunosuppressive environmen…”
BackgroundInfluentialActivation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981 · cited 1×
“This interaction has been shown to be crucial for their interaction with the promoter region of VEGF to enhance angiogenesis in the hypoxic region of the tumors.(118,119) The blockade of STAT3 has been shown to rescue the hypoxia‐ mediated upregulation of the VEGF.”
BackgroundPrinciples of interleukin (IL)-6-type cytokine signalling and its regulation
HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272
STATs: transcriptional control and biological impact
Levy, D. E., & Darnell, J. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm909 · Cited by 3,201
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110 · cited 5×
“STAT3 activity is regulated by various activators and repressors.(3,5) To activate STAT3, a cytokine, such as IL‐6, IL‐10, or IL‐11 binds to a receptor to stimulate JAKs, which mediate the phosphorylation of the tyrosine residue at position 705 (tyr705).”
BackgroundInfluentialVEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721 · cited 2×
“It is mediated by several growth factors including VEGF, PDGF, and angiopoietins.(112,113) Among these growth factors, VEGF has been reported to be one of the most crucial mediators of tumor neovascularization.”
BackgroundThe STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278 · cited 1×
“STATs have a common N‐terminal domain, DNA‐binding region, a coiled‐coiled region, a linker, and SH2 domain.(6,7)”
BackgroundRevisiting STAT3 signalling in cancer: new and unexpected biological functions
Yu, H., Lee, H., Herrmann, A., Buettner, R., & Jove, R. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3818 · Cited by 2,137
Zhong, Z., Wen, Z., & Darnell, J. E. (1994) · Science · doi:10.1126/science.8140422 · Cited by 2,070 · cited 1×
“STAT3 can be activated by cytokines (IL‐6, IL‐8, IL‐10, IL‐35) and growth factors (insulin‐like growth factor, platelet‐derived growth factor (PDGF), epidermal growth factor (EGF), and fibroblast growth factor.(9) The cytokines and growth factors are either secreted by tumors cells itself or by stromal cells, granuloc…”
BackgroundVascular Endothelial Growth Factor and Angiogenesis
Hoeben, A., Landuyt, B., Highley, M. S., Wildiers, H., Van Oosterom, A. T., & De Bruijn, E. A. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.4.3 · Cited by 1,824
Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130
Taga, T., Hibi, M., Hirata, Y., Yamasaki, K., Yasukawa, K., Matsuda, T., Hirano, T., & Kishimoto, T. (1989) · Cell · doi:10.1016/0092-8674(89)90438-8 · Cited by 1,396 · cited 2×
“Briefly, the binding of IL‐6 to IL‐6R (IL‐6 receptor α) results in the conformation changes causing the formation of a hetero‐hexameric complex with gp130 (IL‐6Rβ).(1,5,10,11) This complex activates intracellular signaling through phosphorylation of JAKs and STAT3 (Figure 1).”
BackgroundIliopoulos, D., Hirsch, H. A., & Struhl, K. (2009) · Cell · doi:10.1016/j.cell.2009.10.014 · Cited by 1,374
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
Niu, G., Wright, K. L., Huang, M., Song, L., Haura, E., Turkson, J., Zhang, S., Wang, T., Sinibaldi, D., Coppola, D., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205260 · Cited by 1,207 · cited 7×
“Apart from this, pSTAT3 can form a complex with pc‐Jun and ATF‐2 leading to the induction of CCL5 transcripts in LECs.121 A connection between IL‐6 and VEGF‐dependent angiogenesis in several human tumors including cervical, gastric, breast, glioma, and mesothelioma was found through STAT3 signaling.122–125 This was co…”
BackgroundInfluentialFunction of Mitochondrial Stat3 in Cellular Respiration
Wegrzyn, J., Potla, R., Chwae, Y.-J., Sepuri, N. B. V., Zhang, Q., Koeck, T., Derecka, M., Szczepanek, K., Szelag, M., Gornicka, A., et al. (2009) · Science · doi:10.1126/science.1164551 · Cited by 1,014 · cited 1×
“This study showed that Stat3 can regulate the optimal functioning of the electron transport chain to maintain cellular homeostasis.(132) Several studies support that hyperactivation of the RAS pathway in human cancer is correlated with the localization of STAT3 inside the GARG ET AL.”
BackgroundQuintás-Cardama, A., Vaddi, K., Liu, P., Manshouri, T., Li, J., Scherle, P. A., Caulder, E., Wen, X., Li, Y., Waeltz, P., et al. (2010) · Blood · doi:10.1182/blood-2009-04-214957 · Cited by 843 · cited 1×
“for the treatment of myeloproliferative neoplasms, which are characterized by the aberrant activation of the JAK–STAT pathway by the US Food and Drug Administration (FDA) in 2011 and by the European Medicines Agency in 2012.(335,336) Also, INCB018424 was shown to inhibit the proliferation and induce apoptosis of color…”
BackgroundInterleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells
Sullivan, N. J., Sasser, A. K., Axel, A. E., Vesuna, F., Raman, V, Ramirez, N., Oberyszyn, T. M., & Hall, B. M. (2009) · Oncogene · doi:10.1038/onc.2009.180 · Cited by 757
Mitochondrial STAT3 Supports Ras-Dependent Oncogenic Transformation
Gough, D. J., Corlett, A., Schlessinger, K., Wegrzyn, J., Larner, A. C., & Levy, D. E. (2009) · Science · doi:10.1126/science.1171721 · Cited by 716
Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J.-M., Yang-Yen, H.-F., Karras, J., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci9940 · Cited by 633 · cited 1×
“Activated STAT3 has been reported to increase the expression of Bcl‐2, Bcl‐XL, and Mcl1 proteins to escape the apoptosis of tumor cells.(92,93) STAT3 can induce the expression of survivin for the survival and proliferation of gastric cancer cells.”
BackgroundDrug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells
Lee, H.-J., Zhuang, G., Cao, Y., Du, P., Kim, H.-J., & Settleman, J. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.019 · Cited by 555 · cited 3×
“Also, this study showed that activation of STAT3 is due to feedback from IL‐6 and FGFR cascade.(144) In breast cancer, tamoxifen drug resistance was contributed by the subpopulation of CD44CD24 cells.”
BackgroundInterleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway
Wei, L.-H., Kuo, M.-L., Chen, C.-A., Chou, C.-H., Lai, K.-B., Lee, C.-N., & Hsieh, C.-Y. (2003) · Oncogene · doi:10.1038/sj.onc.1206226 · Cited by 536
Yadav, A., Kumar, B., Datta, J., Teknos, T. N., & Kumar, P. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0271 · Cited by 503
STAT3 Is Required for Proliferation and Maintenance of Multipotency in Glioblastoma Stem Cells
Sherry, M. M., Reeves, A., Wu, J. K., & Cochran, B. H. (2009) · Stem Cells · doi:10.1002/stem.185 · Cited by 478
The multifaceted role of reactive oxygen species in tumorigenesis
Kirtonia, A., Sethi, G., & Garg, M. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03536-5 · Cited by 452 · cited 1×
“prostrate carcinoma.(203,204) Robust activation of STAT3 has been associated with radio and chemoresistance because of an increase in CD133 CSCs in thyroid cancer.”
BackgroundSelf-citationInhibitors of Cytokine Signal Transduction
Wormald, S., & Hilton, D. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.r300030200 · Cited by 440 · cited 1×
“The C‐terminal domain contains the SOCS box to induce E3 ligase dependent proteasomal degradation of JAKs and cytokine receptors.(78,80,81) Different SOCS may act in different ways to regulate STAT signaling.”
BackgroundCorvinus, F. M., Orth, C., Moriggl, R., Tsareva, S. A., Wagner, S., Pfitzner, E. B., Baus, D., Kaufman, R., Huber, L. A., Zatloukal, K., et al. (2005) · Neoplasia · doi:10.1593/neo.04571 · Cited by 427
STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors
Lee, H., Deng, J., Kujawski, M., Yang, C., Liu, Y., Herrmann, A., Kortylewski, M., Horne, D., Somlo, G., Forman, S., et al. (2010) · Nature Medicine · doi:10.1038/nm.2250 · Cited by 395 · cited 4×
“The activation of STAT3 has been shown to enhance the expression of S1PR1 by creating a positive feedback loop in human tumors.(35) Also, the expression of both S1PR1 and STAT3 was reported in B‐cell lymphoma patients.”
BackgroundInfluentialA Critical Role for Stat3 Signaling in Immune Tolerance
Cheng, F., Wang, H.-W., Cuenca, A., Huang, M., Ghansah, T., Brayer, J., Kerr, W. G., Takeda, K., Akira, S., Schoenberger, S. P., et al. (2003) · Immunity · doi:10.1016/s1074-7613(03)00232-2 · Cited by 377
STAT3 controls myeloid progenitor growth during emergency granulopoiesis
Zhang, H., Nguyen-Jackson, H., Panopoulos, A. D., Li, H. S., Murray, P. J., & Watowich, S. S. (2010) · Blood · doi:10.1182/blood-2009-12-259630 · Cited by 232 · cited 1×
“This suggests that STAT3 can partly induce MDSC generation by maintaining C/EBPβ expression.(157) A large number of studies have proved that Treg cells are critical for maintaining the immunosuppressive environment in tumors by acting as a negative regulator for CD8 T cells.”
BackgroundKinjyo, I., Inoue, H., Hamano, S., Fukuyama, S., Yoshimura, T., Koga, K., Takaki, H., Himeno, K., Takaesu, G., Kobayashi, T., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052333 · Cited by 225
Lee, E., Fertig, E. J., Jin, K., Sukumar, S., Pandey, N. B., & Popel, A. S. (2014) · Nature Communications · doi:10.1038/ncomms5715 · Cited by 197 · cited 2×
“Apart from this, pSTAT3 can form a complex with pc‐Jun and ATF‐2 leading to the induction of CCL5 transcripts in LECs.(121) A connection between IL‐6 and VEGF‐dependent angiogenesis in several human tumors including cervical, gastric, breast, glioma, and mesothelioma was found through STAT3 signaling.”
BackgroundHartman, Z. C., Yang, X.-Y., Glass, O., Lei, G., Osada, T., Dave, S. S., Morse, M. A., Clay, T. M., & Lyerly, H. K. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0308 · Cited by 137 · cited 19×
“Also, VEGF has been shown to stimulate VGFR2 to recruit the JAK/ STAT3 pathway which enhances the self‐renewable ability of CSCs.20 This study showed that VEGF treatment induces tumorspheres formation in H23 and MDA‐MB‐231 cells by upregulating the expression of SOX2, MYC.20 Elevated levels of ROS or IL‐6 has been fou…”
BackgroundInfluentialSTAT3, a master regulator of anti-tumor immune response
Rébé, C., & Ghiringhelli, F. (2019) · Cancers · doi:10.3390/cancers11091280 · Cited by 129 · cited 1×
“Another study displayed that STAT3 can increase the immunosuppressive potential of MDSCs either through arginase‐1 in head and neck squamous cell carcinoma (HNSCC) or Indoleamine 2,3‐dioxygenase 1 in breast and liver tumors.(153) The activation of STAT3 in MDSCs was correlated with metastasis and drug resistance.”
BackgroundShinde, A., Hardy, S. D., Kim, D., Akhand, S. S., Jolly, M. K., Wang, W.-H., Anderson, J. C., Khodadadi, R. B., Brown, W. S., George, J. T., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2636 · Cited by 115
Interleukin-6 Induces Both Cell Growth and VEGF Production in Malignant Mesotheliomas
Adachi, Y., Aoki, C., Yoshio‐Hoshino, N., Takayama, K., Curiel, D. T., & Nishimoto, N. (2006) · International Journal of Cancer · doi:10.1002/ijc.22006 · Cited by 115
SOCS proteins in regulation of receptor tyrosine kinase signaling
Kazi, J. U., Kabir, N. N., Flores-Morales, A., & Rönnstrand, L. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1619-y · Cited by 103
Yang, R., Lirussi, D., Thornton, T. M., Jelley-Gibbs, D. M., Diehl, S. A., Case, L. K., Madesh, M., Taatjes, D. J., Teuscher, C., Haynes, L., et al. (2015) · eLife · doi:10.7554/elife.06376 · Cited by 91 · cited 1×
“A study reported that IL‐6 can induce the activation of CD4+ T cells which is dependent on mSTAT3 to regulate activity of complex 1, mitochondrial membrane polarization, and mitochondrial Ca.(142) Moreover, mSTAT3 has been shown to be critical for malignant transformation in a variety of oncogenic pathways including R…”
BackgroundGlutamine activates STAT3 to control cancer cell proliferation independently of glutamine metabolism
Cacace, A., Sboarina, M., Vazeille, T., & Sonveaux, P. (2017) · Oncogene · doi:10.1038/onc.2016.364 · Cited by 76
Cited by
The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
Emerging role of exosomes in cancer progression and tumor microenvironment remodeling
Paskeh, M. D. A., Entezari, M., Mirzaei, S., Zabolian, A., Saleki, H., Naghdi, M. J., Sabet, S., Khoshbakht, M. A., Hashemi, M., Hushmandi, K., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01305-4 · Cited by 563
Self-citationMirzaei, S., Saghari, S., Bassiri, F., Raesi, R., Zarrabi, A., Hushmandi, K., Sethi, G., & Tergaonkar, V. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30759 · Cited by 243
Self-citationDatta, A., Deng, S., Gopal, V., Yap, K. C.-H., Halim, C. E., Lye, M. L., Ong, M. S., Tan, T. Z., Sethi, G., Hooi, S. C., et al. (2021) · Cancers · doi:10.3390/cancers13081882 · Cited by 184
Self-citationCelastrol in cancer therapy: Recent developments, challenges and prospects
Lim, H. Y., Ong, P. S., Wang, L., Goel, A., Ding, L., Li-Ann Wong, A., Ho, P. C.-L., Sethi, G., Xiang, X., & Goh, B. C. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.030 · Cited by 118
Self-citation
Metadata
- Authors
- Garg, M., Shanmugam, M. K., Bhardwaj, V., Goel, A., Gupta, R., Sharma, A., Baligar, P., Kumar, A. P., Goh, B. C., Wang, L., & Sethi, G.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2020-12
- Volume
- 41
- Issue
- 3
- Pages
- 1291-1336
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W3108673912
- Cited by
- 139
- References
- 45
- FWCI
- 7.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.